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ABSTRACT 
Cationic double chain surfactants have attracted much interest because they can give rise 
to cationic vesicles that can be used in biomedical applications. Using a simple and 
economical synthetic approach, we have synthesized four double-chain surfactants with 
different alkyl chain lengths (LANHCx). The critical aggregation concentration of the 
double chain surfactants is at least one order of magnitude lower than the CMC of their 
corresponding single-chain LAM and the solutions prepared with the LANHCx contain 
stable cationic vesicles. Encouragingly, these new arginine derivatives show very low 
haemolytic activity and weaker cytotoxic effects than conventional dialkyl dimethyl 
ammonium surfactants. In addition, the surfactant with the shortest alkyl chain exhibits 
good antimicrobial activity against Gram-positive bacteria. The results show that a 
rational design applied to cationic double chain surfactants might serve as a promising 
strategy for the development of safe cationic vesicular systems.  
 
 
 
Keywords : cationic vesicles, arginine-based surfactants, antimicrobial activity, cytotoxicity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
INTRODUCTION 
Development of dialkyl cationic surfactants has attracted considerable interest because of 
their use in biomedical applications [1]. Due to their molecular geometry, these types of 
amphiphiles give rise to niosomes with a cationic charge that can be used as drug delivery 
systems or gene therapy [2]. These therapeutic applications require the use of stable 
surfactants under sterilization conditions that present low haemolytic or cytotoxic 
activity.  Several cationic lipids such as DOTMA (1,2-di-O-octadecenyl-3-
trimethylammonium propane) or DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) 
have been used to prepare cationic niosomes for pharmaceutical applications [3], but the 
production of such lipids on a large scale is very expensive. Alternatively, dialkyl 
dimethyl ammonium bromide surfactants can be prepared at reasonable cost and these 
surfactants also form cationic niosomes and show antimicrobial activity [4]. However, 
their use is seriously questioned from an environmental point of view as quaternary 
ammonium surfactants are toxic to aquatic organisms and not biodegradable [5-6-7].  
In general, quaternary ammonium surfactants are more toxic than surfactants with the 
cationic charge delocalized in a heterocyclic ring or guanidine group [8]. Over the last 
years, our research group has studied N-acyl arginine derivative surfactants that consist 
of one alkyl chain linked to the α-amino group of the arginine methyl ester. These 
surfactants present physicochemical properties similar to those of classic cationic 
surfactants, but they show high biodegradability, low toxicity against aquatic 
microorganisms and moderate toxicity against human cell lines. Additionally, these 
compounds can be easily prepared from renewable raw materials [9].  
In this work, we have prepared new double-chain cationic surfactants from arginine using 
the single-chain Nα-lauroyl-arginine methyl ester (LAM) as starting material (Figure 1). 
The new compounds consist of one arginine as the cationic polar head and two alkyl 
chains linked to the arginine through amide bonds (Figure 1). For the newly prepared 
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surfactants, we have studied the micellization process, their ability to form cationic 
niosomes in water solutions as well as the size distribution and zeta potential of the 
cationic vesicles. Moreover, their antimicrobial activity and cytotoxicity have been 
determined in order to explore their potential applications. This work may represent a 
step forward in the development of non-toxic and stable colloidal systems to be used in 
pharmaceutical applications. 
MATERIALS AND METHODS 
This section briefly describes the methods used in this work, and more details are reported 
as supplementary information. 
The progress of the reactions as well as the purity of the final compounds was monitored 
by HPLC, Merck-Hitachi D-2500 model using a UV-VIS detector L-4250 at 215 nm. The 
structures of the pure compounds were examined by 1H and 13C nuclear magnetic 
resonance analyses, recorded on a Varian spectrometer at 499.803(1H) and 125.233 (13C) 
MHz, respectively. Chemical shifts () are reported in parts per million (ppm) downfield 
from tetramethylsilane (TMS). Mass spectroscopy (MS) spectra with fast atom 
bombardment (FAB) or electrospray techniques were carried out with a VG-QUATTRO 
from Fisons Instruments. (S.I.2 and S.I.3) 
Conductivity 
Conductivity was measured using an Orion Cond. Cell 011010A with platinized platinum 
electrodes in conjunction with a Thermo Orion 550A with a cell constant of 0.998 cm-1. 
Samples for conductivity measurements were prepared by weight in Millipore ultra-pure 
water.( S.I.3.) 
Surface tension  
 
The surface tension was measured using a home-made pendant drop surfactometer. A 
surfactant solution drop is created at the end of a straight cut Teflon tube with a 0.8 mm 
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internal diameter and a 1.58 mm external diameter The image of the drop is taken using 
a web cam. The image is corrected for spherical aberration. The droplet contour is taken 
at the point of maximum intensity slope. This contour is fitted to the Laplace –Young 
equation [10] using a Golden Section Search Algorithm that has the centre coordinates, 
an angular correction for the vertical alignment, the radius of the droplet and the 
interfacial tension as parameters.  
Vesicles preparation 
Surfactants, adequately weighed, were dissolved in methanol.  The organic solvent was 
vacuum dried and the resulting lipid film was hydrated under sonication (30 minutes at 
50 ºC) with deionized water (Table 1).  
TABLE 1 
Size distribution and ζ -potential 
The ζ-potential of the formulations was measured by laser Doppler electrophoresis using 
the Zetasizer 2000 (Malvern Instruments Ltd., Malvern, U.K.), at 25°C. Analyses were 
done in triplicate.  
 Dynamic Light Scattering (DLS) was used to measure the size distribution of all 
formulations. The DLS unit was a Malvern Zeta Nanosizer, working at 632.8 nm and 
25ºC. The scattering intensity was measured at a 173º angle to the incident beam [11]. At 
least 10 runs were performed for each sample. The measured correlation was used to 
calculate the size distribution. The size distribution profile was determined with the 
CONTIN algorithm [12] which allows working with monomodal as well as multimodal 
distributions.  
Antimicrobial activity 
a) MIC determinations 
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Antimicrobial activity was determined “in vitro” on the basis of the minimum inhibitory 
concentration (MIC) [13], defined as the lowest antimicrobial agent concentration that 
inhibits the development of visible growth after incubation at 37 ºC for 24 hours (S.I.5). 
Cytotoxicity evaluation  
Cell line cultures. 3T3 (murine Swiss albino fibroblasts), HaCaT (spontaneously 
immortalized human keratinocytes) and human epithelial cervical cancer HeLa cell lines 
(Eucellbank, Barcelona). 
Chemical exposure. Stock solutions of surfactants were prepared in DMSO at a 
maximum concentration of 10 mg/mL. Serial dilutions were subsequently prepared in 
DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 5% FBS (phosphate 
buffer saline), 2 mM L-glutamine, and 1% antibiotic solution (final concentration of 
DMSO in culture medium < 1%). After removal of the medium culture, 3T3, HaCaT or 
HeLa cells were exposed to the surfactants in multi-well plates. Controls containing only 
culture medium were included in each plate, and they were independent for each of the 
different surfactants tested. Plates were incubated at 37 ºC, 5% CO2 for 24 hours. 
The cytotoxicity of surfactants against these three cell lines was determined using a 
tetrazolium-based assay (MTT) [14] and the NRU assay. (S.I.6) 
 Haemolysis assay. We followed an adaptation of the method described by Pape et al. 
[15].  ( S.I.6) 
Synthesis  
Synthesis of LANHCn. 0.0035 moles of LAM, synthesized as reported in the literature 
[16], were weighed into a round flask. Then 0.014 moles of the corresponding fatty amine 
were added. The mixture was heated to the melting point of the amine and was stirred at 
this temperature for three hours. After the completion of the reaction, the mixture was 
cooled at room temperature and several crystallizations in methanol/acetonitrile were 
8 
 
carried out to remove the excess of fatty amine. The identification of the products was 
performed by HPLC, 1 HNMR and 13 CNMR, Mass Spectroscopy and Elemental analysis 
(Supporting Information)  
RESULTS AND DISCUSSION 
 
Cationic vesicles have great potential in new biomedical applications. They can be used 
as antimicrobial systems, in gene delivery and as vesicles for drugs. The aim of this work 
is to design and synthesise new biocompatible surfactants that give rise to nontoxic 
cationic vesicles in the aqueous medium.   
 
Synthesis 
 
Surfactants based on renewable raw materials are characterized by their low negative 
impact on the environment. In this work, we have prepared one single-chain surfactant 
and four double-chain surfactants using renewable resources and a clean and rapid 
synthetic methodology. 
 The LAM can be classified as biocompatible and biodegradable due to its biological 
properties. It has been synthesized following the procedure previously reported by us. [9]. 
The compounds with two alkyl chains were obtained by simply heating the LAM with 
the corresponding amine without using any solvent (Figure 1). In these conditions, the 
percentage of conversion is always higher than 90% after 2 hours and the reaction does 
not require the use of any activating agent. This approach allowed us to perform the 
synthesis in a short time and on a large scale and at a reasonable cost.  
These cationic double chain surfactants have amide linkages between the polar head and 
the hydrophobic chains. Usually, the introduction of an ester or amide linkage between 
the alkyl chain and the hydrophilic moiety improves the biodegradation of surfactants 
[17].  
FIGURE 1 
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Critical aggregation concentration 
 
The concentration at which the surfactant molecules start to form aggregates in aqueous 
solutions was determined by tensiometry and conductivity. The LANHCx surfactants are 
sparingly soluble in water; therefore, the most concentrated samples had to be prepared 
by sonication of the aqueous solution during 10 minutes at 45 ºC. All samples give rise 
to bluish solutions, indicating the presence of big aggregates. Previous studies showed 
that the single-chain LAM formed transparent solutions that contained spheroidal 
micelles [18]. The critical packing parameter (CCP) considers the geometry of the 
molecule to predict what type of structures can be formed when monomers start to 
aggregate [19]. Usually, double-chain surfactants have a cylindrical shape with CPP 
values between 0.5 and 1. This shape explains why these surfactants have low 
spontaneous curvature and tend to form planar structures like lamellar bilayers and 
vesicles while the conically shaped single-chain surfactants form spherical micelles. 
According to the above considerations, the surfactants studied in this work are expected 
to form vesicles or big aggregates, therefore the concentration at which these surfactants 
start to form aggregates in solution will be denoted as the critical aggregation 
concentration (CAC).  
TABLE 2 
The surface tension/concentration plots show only one breakpoint in the 0.01-0.1 mM 
concentration range corresponding to the CAC values (Table 2). These results suggest 
that vesicles are formed directly at low concentrations. Double chain surfactants that form 
micelles and vesicles show two transition points in the surface tension curves [20]. It has 
been reported that surfactants with one arginine or lysine and two alkyl chains also form 
vesicles in aqueous solutions [21]. The didodecyl dimethylammonium bromide, a widely 
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studied double chain cationic, forms lamellar bilayers or vesicles, and the critical 
aggregation is denoted as CVC (critical vesicular concentration) [22-23-24].  
The incorporation of the second alkyl chain into the LAM enhances the hydrophobic 
character of the molecule and consequently causes a significant decrease of the CAC 
(Table 2). The difference in the CAC between LANHC12 and LAM is more than one order 
of magnitude. The CAC of gemini surfactants from arginine with two alkyl chains of 
twelve carbon atoms is also higher than that found for these double-chain derivatives. 
Para et al. [25] also found that the surface activity of the gemini surfactant was somewhere 
in between the surface activity of the monomeric and that of the dimeric surfactant.  
The CAC in aqueous medium varies little with the change in alkyl chain length of one of 
the hydrophobic chains. First, the CAC slightly decreases from n=10 to n=14 and then it 
rises for n=18. For single-chain ionic surfactants, the CAC decreases abruptly as the 
number of carbon atoms in the hydrophobic group increases. However, for very 
hydrophobic surfactants the CAC does not decrease so rapidly with increase in the length 
chain, and when the chain exceeds 18 carbons, it may remain substantially unchanged 
[26] The presence of a carbon-carbon double bond in LANHC18 gives rise to a bulky 
hydrophobic group. The increase of the CAC is probably due to the difficulty of 
incorporating the bulky hydrophobic group in the interior of the micelle. 
Table 2 also contains the effectiveness of these surfactants in decreasing the surface 
tension of water (π) as well as the minimum area per molecule at the interface (Am) (S.I.4). 
Double chain surfactants are more effective reducing the surface tension than the single-
chain LAM. The presence of two alkyl chains results in close packing at the interface and 
consequently the surface tension at the CAC decreases. Among the LANHx compounds, 
the effectiveness decreases by increasing the length of one alkyl chain. The Amin of the 
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double-chain derivatives is similar to that of LAM. This suggests that, due to the presence 
of two hydrophobic chains, the LANHCx compounds are tightly packed at the interface. 
FIGURE 2 
The curve of conductivity against surfactant concentration at 25 and 50 ºC for LANHC14 
is shown in Figure 2. Similar curves have been obtained for the other surfactants, and the 
CAC values obtained at both temperatures are included in Table 2. The CAC of LANHC18 
was measured by conductivity at 50 ºC only since it was difficult to achieve stable values 
of conductivity at 25 ºC. Only one breakpoint was detected in all cases confirming that 
these surfactants form big aggregates directly. Moreover, the temperature does not affect 
the CAC values. The CAC values obtained by conductivity are slightly higher than those 
obtained by surface tension measurements. The discrepancy between surface tension 
measurements and determinations by bulk techniques to obtain the CMC/CAC is present 
in the literature. [27-28]. 
 
Cationic vesicles prepared with double chain arginine surfactants 
In this work we have explored the capability of cationic dialkyl arginine derivatives to 
form vesicles. These aggregates were prepared following the procedure described in the 
experimental section. 
After preparation, vesicles were left for 3 hours at room temperature and then the diameter 
and size distribution was measured at 25 ºC using dynamic light scattering measurements 
(DLS). All solutions were then heated again for 60 minutes at 50ºC and the diameter and 
size distribution were evaluated at 50 ºC. Afterwards, the formulations were kept at room 
temperature for 6 months. 
FIGURE 3 
12 
 
The image in Figure 3 shows the dispersions at three different concentrations (1, 2.5 and 
5 mm). The samples´ visual appearance provides valuable information. It is known that a 
change in the turbidity of a surfactant solution can be related to the change in the amount 
and/or the size of the aggregates. The LANHC10 forms a bluish translucent solution at 1 
mM. By increasing the concentration, the solutions became milky and turbid (Figure 3). 
All solutions of LANHC12 appeared as bluish and viscous dispersions with the typical 
aspect of vesicular formation. The appearance of LANHC14 solutions is similar to those 
based on LANHC12, with a slight intensification of turbidity. After the second heating 
cycle, all samples appear less turbid. Finally, some evidence of phase separation has been 
observed after 1 month for the most concentrated samples of LANHC10 and after 2 
months for the LANHC10 1 mM solution. Formulations based on LANHC12, LANHC14 
and LANHC18 remained stable for 6 months.  
TABLE 3 
Table 3 shows the particle size and size distribution data obtained for LANHCx based 
formulations and Figure S1 (Supporting information) shows the size distribution profiles. 
At room temperature, LANHC10 solutions contain large vesicles (diameters >1000 nm) 
and at 50ºC the diameter of the aggregates is still high. At room temperature LANHC12 
solutions show high polydispersity and contain giant vesicles (diameters >1000 nm). 
However, at 50ºC these samples show only one peak with an average diameter in the 
range 150-300 nm. Samples based on LANHC14 show a very similar behaviour. However, 
the sample prepared with LANHC18 at 1 mM is a translucent solution that contains small 
aggregates (about 60 nm) at 25 and 50 ºC.  From the results, it is not possible to establish 
how the alkyl chain length affects the vesicle’s size. For 1 mM samples, the vesicle’s size 
decreases as the alkyl chain increases, especially for n=18. However, the more 
concentrated formulations appear not to follow this trend.  
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These results correlate well with the stability of samples. Formulations that contain very 
large vesicles show phase separation after 1 or 2 months while those that contain medium 
size vesicles remain stable for more than 6 months. The stability can also be related to the 
repulsive interactions among aggregates with positive charges. As expected, large 
positive ζ-potential values have been obtained for vesicles prepared with these surfactants 
(61.4 mV for LANHC10, 48.3 mV for LANHC12, 36.6 mV for LANHC14 and 18 for 
LANHC18). The positive charge density of the aggregates is strong enough to ensure that 
no coagulation occurs for LANHC12, LANHC14 and LANHC18 formulations. In the case 
of LANHC10 the large sizes observed can result in large van der Waals attractive forces 
between vesicles that allow these aggregates to overcome the repulsive electrostatic 
forces and induce phase separation. It has been described that vesicles prepared with 
mechanical forces, like ultrasonication, are metastable.29  For example, sonicated DDAB 
vesicles with high z potentials were unstable, resulting in phase separation [30]. However, 
when the size of these DDAB vesicles is reduced, the aggregates are stable for extended 
periods of time as a result of repulsive electrostatic forces.  
The preparation procedure also can strongly affect the size of the vesicle.  Different 
vesicle sizes have been reported for the same compound. Feitosa el al. reported DDAB 
vesicles prepared at room temperature with a diameter of 195 nm [31]. For DDAB and 
dioctadecyl dimethylammonium bromide (DODAB) the diameters of spontaneously 
formed vesicles were 70 nm [32] and 674 nm [33] respectively. After bath sonication of 
the dispersion, the diameter of the DODAB vesicles dropped to 44 nm [34], and to 66 nm 
after tip sonication [35]. Kondo el al. [30] showed that the DDAB vesicles´ diameter 
decreased with ultrasonication time, reaching a limiting value of approximately 17 nm 
after about 1.5 h.  
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To summarize, it can be stated that these compounds form large and stable vesicles at 
room temperature. The size of niosomes formulated with these compounds exhibits strong 
temperature dependence. DLS measurements at 25 ºC show a major population of very 
big aggregates in the micrometre range with a large polydispersity. When heated to 50 ºC 
the polydispersity, as well as, the size of the aggregates decrease drastically. This 
behaviour could be due to the state of the niosomes. In general, vesicular dispersions 
scatter more light in the gel than in the liquid-crystalline state owing to formation of large 
or more complex vesicular structures [31]. 
 
Antimicrobial activity 
In this work, we have evaluated how the incorporation of a second alkyl chain affects the 
antimicrobial activity of LAM [16]. Table 4 shows that the antimicrobial activity of these 
new surfactants is lower than that of LAM, probably due to their high hydrophobicity. 
The low antimicrobial activity of the new surfactants can also be related to their 
aggregation behaviour. For LAM the MIC values occur at concentrations below the CMC. 
Therefore, monomers are the species that interact with the cells. However, the aggregation 
of LANHCx takes place at very low concentrations, and they form vesicles instead of 
micelles. Hence, in this case, the vesicles have to interact with the cellular membranes. 
Recent studies have shown that for colloidal suspensions prepared with arginine-based 
gemini surfactants the antimicrobial and haemolytic activity increases as the aggregate’s 
size decreases [36]. Vieira et al. who studied the antimicrobial and haemolytic activity of 
DODAB (dioctadecyl dimethylammonium bromide) bilayer fragments and DODAB 
large vesicles and also found that small aggregates penetrate more deeply into the cell 
surface, and, consequently have lower MIC and HC50 values [37]. It has also been 
reported that niosomes containing monoalkyl surfactants from methylprolinolinium show 
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good antimicrobial activity while niosomes formulated with the dialkyl homologue do 
not show biological activity. These authors suggested that the lateral homogeneity of the 
niosomes´ bilayer could be another important parameter that controls their biological 
activity [38-39]. Whereas niosomes prepared with single chain surfactants had Tm values 
around 27 ªC, double chain cationic surfactants gave rise to niosomes with a high Tm (40 
ºC). Therefore, at 37 ºC the single chain surfactants are in the LC phase while the double 
chain ones are in the solid ordered phase, and the bilayers have poor lateral miscibility.  
TABLE 4 
The antimicrobial activity of these new surfactants depends on hydrophobicity, although 
the correlation between hydrophobicity and antimicrobial activity is not linear. The 
LANHC10, the less hydrophobic and most active surfactant, shows antimicrobial activity 
against most of the microorganism tested. However, the LANHC12 and LANHC14 show 
a moderate activity only against Gram-positive bacteria and LANHC18 did not show 
activity against any of the microorganisms. 
As expected, Gram-negative bacteria were more resistant than Gram-positive bacteria. 
These bacteria have a hydrophilic surface due to the side chains of the LPS which hinders 
hydrophobic molecules from entering the bilayer [40]. 
 
Cytotoxicity 
The concentration that induces haemolysis of 50% of the erythrocytes (HC50) was 
determined and quantified from plots of percentage of haemolysis as a function of 
surfactant concentration.  
The low haemolytic activity of LANHC10, LANHC12 and LANHC14 is noteworthy (Table 
5). For cationic surfactants, these HC50 concentrations are exceptionally high.  The 
surface of red blood contains negative charges, which prevents their self-aggregation and 
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makes them as colloids suspended in blood [41]. For this reason, cationic surfactants can 
interact well with the negatively charged surface of erythrocytes.  
TABLE 5 
Compared with the LAM, (HC50= 144µM) [42] the haemolytic activity of these 
compounds is exceptionally low (Table 5). This could be ascribed to the size and stability 
of the aggregates that they form. Notice that, except the LANHC18, all LANHCx 
surfactants form large and stable giant vesicles at 25 ºC. In general, single-chain 
surfactants are less haemolytic than the corresponding double-chain surfactants with a 
gemini structure [43]. However, the haemolytic character of gemini surfactants from 
arginine with alkyl chains of 12 carbon atoms and long spacer chains is considerably 
lower than that of LAM, probably due to the small size of the gemini aggregates [36]. 
Carmona-Ribeiro et al. also found that solutions of the single chain derivative hexadecyl 
trimethylammonium bromide (HC50=0.7 µM) are more haemolytic than those of large 
vesicles formed by the double-chain compound dioctadecyl dimethylammonium bromide 
(HC50 = 4.0 µM) [37].  
It should also be considered that the vesicles’ stability can also affect their haemolytic 
character. It has been described that haemolysis was induced immediately after the 
addition of dialkyl dimethylammonium surfactants with relatively short alkyl chains (10 
carbon atoms) while haemolysis was gradually induced for long alkyl chains (16 and 18 
carbon atoms). This behaviour was ascribed to the stability of the vesicles formed by these 
compounds.  Haemolysis is induced by the penetration of the monomer into the 
erythrocyte membrane. Vesicles of dialkyl dimethylammonium with short chains appear 
unstable and may easily become monomers. However, dialkyl dimethylammonium 
surfactants with long hydrophobic chains form more stable vesicles or aggregates, 
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because of that the presence of monomers was reduced and haemolytic activity decreased 
[44]. 
The haemolytic activity of these surfactants increased considerably by increasing the 
length of the second alkyl chain. The influence of the hydrophobic domain (alkyl chain 
length and number of hydrophobic chains) on cellular toxicity is not well established in 
the literature. There are some surfactant analogues in which haemolysis increases with 
the elongation of the alkyl chain [45-46] whereas, in other groups, haemolysis decreases 
as the alkyl chain increases [47]. Fogt et al. [48] and Lv et al. [8] also reported that for 
aliphatic chains, single-chain cationic lipids are more toxic and less efficient than their 
double-chain counterparts whereas Tang and Hughes [49] demonstrated that the single-
chain 6-lauroxyhexyl ornithinate presented lower cytotoxicity than DOTAP, a double-
chain cationic surfactant widely used in gene therapy.  It is, therefore, essential to 
accurately characterize the physicochemical and biological properties of new surfactants 
to obtain data that allow correlating results with toxic effects and help to develop novel 
and safe cationic lipids. 
To summarize, it can be stated that the haemolytic activity of LAM [42] is lower than that 
of standard monoQuat surfactants with comparable CMC values and the haemolytic 
character of gemini surfactants from arginine with long spacer chains [36] is much lower 
than that of bis(Quats) gemini surfactants [50] or gemini surfactants based on pyridinium 
salts [51]. Our results also indicate that the haemolytic activity of arginine-based double 
chain surfactants is also much lower than that of double chain surfactants with the cationic 
charge on a quaternary ammonium [37]. Then it can be concluded that for similar 
chemical structures, cationic surfactants from arginine, in which the cationic charge is 
located on the guanidine group, are less haemolytic than QUATS. 
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The cytotoxic effects of these surfactants were evaluated with 3T3, HaCaT and HeLa 
cells using two different endpoint assays (Table 5). The combination of different cell lines 
and cytotoxicity assays gives information concerning general and specific toxicological 
mechanisms [52]. 
All these cationic surfactants induced a clear dose-response relationship, which allowed 
us to determine the half maximal inhibitory concentration or IC50.  The toxicity depends 
on both the cell line tested and the end point assay. HaCat, 3T3 and HeLa cells are much 
more fragile than red blood cells to the vesicles formed by these surfactants. Moreover, 
the IC50 values obtained using the MTT assay are lower than those obtained with the NRU 
assay. These differences can be ascribed to the cytotoxicity mechanisms evaluated by the 
different biological assays. Haemolysis depends on the interaction of surfactants with the 
plasma membrane of a cell. The MTT assay is a measurement of cellular metabolic 
activity within the mitochondrial compartment while the NRU assay measures membrane 
integrity. Taking into account the cell damage evaluated by every assay, our results 
suggest that the aggregates formed by the LANHCx derivatives interact first with the 
mitochondrial compartment affecting cellular metabolism while the plasma membrane is 
less affected. These differences also suggest that the internalization of the compound is 
produced before cell membrane damage. Similar behaviour has been described for single 
and double-chain surfactants from lysine [53] as well as for cationic nanovesicular 
systems containing lysine-based surfactants [54]. 
The toxicity showed by these surfactants is lower than those reported for double-chain 
surfactants from arginine and lysine with a gemini structure [42-43]. However, double 
chain surfactants from arginine with a glycerolipid structure exhibited lower toxicity 
possibly due to their lower chemical stability [42]. The chemical bond linking the head 
group to the two hydrophobic chains can affect toxicity. Glycerolipid surfactants from 
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arginine contain two alkyl chains linked to the head group by ester bonds. These ester 
bonds can be easily hydrolysed giving rise to non-toxic species.  
Our results clearly show that the incorporation of the second alkyl chain on LAM 
increases the cytotoxicity against the 3T3, HaCat and HeLa cell lines. This behaviour 
contrasts with that observed for the haemolytic activity and indicates that the mechanisms 
that dominate the interaction of LAM or double-chain derivatives aggregates ( micelles 
for LAM or vesicles for the double-chain compounds) with red blood cells and the other 
cell lines are different. These results are in line with previous studies that reported that 
cytotoxic effects of carrier systems differ depending on the cell lines used due to the 
nature of these cells [55]. 
It seems that cytotoxicity slightly decreases by increasing the length of one of the 
hydrophobic chains. In fact, the lowest cytotoxicity was obtained for the LANHC18. 
Notice that vesicles formed by this surfactant have the lowest surface cationic charge. 
Cell membranes have large negatively charged domains. It has been described that 
cationic vesicles interact with cell membranes neutralizing the sialic acid groups and 
changing the surface charge from negative to positive [56]. Then, because of electrostatic 
interactions a great affinity of vesicles with high cationic charge density is expected.  
The IC50 values suggest that the aggregate’s size does not affect the cytotoxicity against 
the three cell lines tested. The influence of aggregate’s size on cellular toxicity is not 
clearly explained in the literature. In fact, some researchers have proposed that cells more 
easily take up smaller particles [57-36] while other studies suggest that the size of 
nanoparticles does not influence cytotoxicity [58]. 
In general, dialkyl dimethylammonium bromides with similar alkyl chain lengths showed 
higher cytotoxicity than these arginine derivatives. For example, the IC50 of DDAB 
against erythroleukemic cells was 0.85 μM [59].  
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It should be noticed that overall, vesicles formed by pure cationic lipids can exhibit 
toxicity, but this can be reduced adding another compound to the vesicular system. At 
100 μM the cell viability of vesicles prepared with pure DODAB (dioctadecyl 
dimethylammonium bromide), DHDAB (dihexadecyl dimethylammonium bromide) and 
DMDAB (dimiristoyl dimethylammonium bromide) is about 30%, 20% and 5% 
respectively. However, at this same concentration, the cell viability rises up to more than 
60% when the vesicles are formulated with these cationic surfactants together with a 
neutral phospholipid [60]. The haemolytic activity of negatively charged vesicles 
prepared with mixtures of diacylglycerol arginine-based 
surfactants/phosphatidylglycerols was much lower than those prepared with the cationic 
surfactant alone.61 Moreover, it has been reported that cationic niosomes prepared with 
mixtures of DODAB, DPPC and cholesterol showed very low toxicity against B16F10 cell 
lines (IC50> 3.12 mM) [1b]. For this reason, studies of the effect of adding neutral 
phospholipids on cationic vesicles prepared with these surfactants are underway. The aim 
is to know if this procedure reduces the cellular toxicity of these cationic formulations. 
 
CONCLUSIONS 
Four novel double-chain surfactants with different hydrophobic chain lengths have been 
prepared from the biocompatible Nα-Lauroyl arginine methyl ester (LAM). The synthetic 
approach used allows for the preparation of these new compounds on a large scale, at a 
reasonable cost and low ecological impact. 
The CAC of these new cationic surfactants is much smaller than that shown by the single-
chain homolog LAM. Because of their molecular architecture consisting of one polar head 
and two alkyl chains, they form cationic vesicles at very low concentrations. Our results 
indicate that by introducing a second alkyl chain on the single-chain surfactant LAM it is 
possible to obtain new compounds that form stable cationic vesicles in aqueous solutions 
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and present very low haemolytic activity. Moreover, cationic vesicles prepared with the 
LANHC10 also have good antimicrobial activity against Gram-positive bacteria. In vitro 
studies with 3T3, HaCaT and HeLa cells show that these double arginine surfactants 
exhibit weaker cytotoxic effects compared to conventional dialkyl dimethylammonium 
surfactants. These compounds can be suitable candidates to be used in biotechnological 
and pharmaceutical applications because of both the synthetic procedure required for their 
preparation as well as their properties. Finally, it should be remarked that understanding 
the physicochemical properties of the cationic surfactants in association with their 
biological properties can lead to a rational design of safe cationic lipids.  
ACKNOWLEDGEMENTS 
The authors would like to thank the Spanish Plan National I+D+I MAT2012-38047-C02-
02, MAT2012-38047-C02-01, MIMECO-CTQ2013-41514-P, MIMECO-CTQ2014-
59632-R and the “Grupo de Tensioactivos con Membranas Celulares” (Universitat de 
Barcelona), Unidad asociada CSIC. 
 
 
 
 
 
Highlights 
 
1. Cationic double chain arginine based surfactants have been prepared using a 
simple and economical synthetic approach. 
2. Stable cationic vesicles have been prepared using double chain arginine 
surfactants. 
3. The antimicrobial activity of these cationic vesicles depends on the alkyl chain 
length of the surfactant. 
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4. The low haemolytic activity of vesicles prepared with these double chain 
derivatives is noteworthy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLES 
 
Table 1. Details of sample preparation. All solutions have been prepared using 5 mL of water. 
 LANHC10 
(mg) 
LANHC12 
(mg) 
LANHC14 
(mg) 
LANHC18 
(mg) 
1 mM 2.7 2.8 2.9 3.2 
2.5 mM 6.7 7 7.2  
5 mM 13.5 14 14.4  
10 mM 27 28 29  
23 
 
*Weights measured with 0.01 mg precision. 
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Table 2. CAC values obtained by surface tension and conductivity measurements as well as the 
surface tension at the CVC (γcmc), the effectiveness (π) and the area per molecule (Amin) for the 
LAM and the double chain cationic surfactants are shown. 
Surfactant CACa 
Conductivity 
mM 
CACa 
Surface tension 
mM 
γcmcb 
mN/m 
Πb Aminc 
nm2 
 
LAM 1 
 
5.4 ± 0.02 
 
5.8 ± 0.5 
 
32 ± 1 
 
40 ± 1 
 
0.67 ± 0.21 
 
LANHC10 0.29 ± 0.02 
0.33 ± 0.02* 
 
0.14 ± 0.01  24 ± 1   48± 1  1.02±0.24 
LANHC12 0.12 ± 0.01 
0.13* ± 0.01 
 
0.055± 0.006  24 ± 1   48 ± 1 0.65±0.33 
LANHC14 0.080 ± 0.005 
0.090 ± 0.005* 
 
0.035 ± 0.003 30 ± 1    42 ± 1 0.73±0.33 
LANHC18 ---- 
0.072 ± 0.004 * 
0.090 ± 0.009 28 ± 1   44 ± 1 1.04±0.27 
 
1CAC value obtained from reference 9 
*CAC obtained at 50 ºC 
aThe CAC errors correspond to the 95% confidence interval obtained from the crossing point of two straight 
lines. 
b γ and Π errors correspond to 95% confidence intervals determined for the technique. 
c Amin errors correspond to the 95% confidence interval obtained from the slope incertitude and error 
transmission.  
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Table 3. Effect of the concentration on the size and stability of vesicles prepared with the 
arginine surfactants 
  
Tª (ºC) 
 
 
Visual aspect and stability 
Populations 
(Diameter, nm) 
    
PdI 
LANHC10 1mM 25 Bluish solution, Giant vesicles 4172 nm, 94 nm  
50 Bluish translucent 279 nm 0.200 
LANHC10 2.5mM 25 
 
Presence of giant vesicles 
PRECIPITATION 
318 nm, 4040 nm 
80 nm 
0.710 
50 
 
Presence of giant vesicles 
PRECIPITATION  
1590 nm 
167 nm 
0.592 
LANHC10 5mM 25 Very turbid 
Non measurable 
  
50 Giant vesicles  
PRECIPITATION 
1302nm, 202 nm 
 4893 nm 
0.574 
LANHC10 10 mM 25 Very turbid, Non measurable 
PRECIPITATION 
  
50 Two populations 
PRECIPITATION 
1410 nm 
53 nm 
1 
LANHC12 1mM 25 Bluish solution, very dispersed 
population with giant aggregates  
1419 nm, 169 nm 
5212 nm 
0.506 
50 Bluish translucent 
 
306 nm 0.194 
LANHC12 2.5mM 25 Bluish solution  851 nm 
155 nm 
0.521 
50 Bluish solution 185 nm 0.376 
LANHC12 5mM 25 Bluish solution 1351 nm, 152 nm 
4579 nm 
1.0 
50 Clear bluish solution 
 
91.5 nm 0.318 
LANHC12 10 mM 25 Not measurable   
50 Clear bluish solution 212 nm 0.229 
LANHC14 1mM 25 Bluish solution  203nm 0.200 
50 Bluish translucent 227 nm 0.134 
LANHC14 2.5mM 25 Very turbid and bluish solution 
Not measurable 
  
50 Bluish translucent 242 nm 0.112 
LANHC14 5mM 25 Very turbid and Bluish solution 
Not measurable 
  
50 Bluish solution  176 nm 0.076 
LANHC14 10 mM 25 Very turbid and Bluish solution 
Not measurable 
  
50 One population 203 nm 0.113 
LANHC18 1 mM 25 Bluish solution 60 nm  
50 Bluish translucent 60 nm 0.265 
*The size distribution profiles are shown in Figure S1 (Supporting Information) 
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Table 4. Antimicrobial activity expressed as minimum inhibitory concentration (MIC) of the 
double chain arginine based surfactants. 
Microorganisms LAM1 
(µM) 
LANHC10 
(µM) 
LANHC12 
(µM) 
LANHC14 
(µM) 
LANHC18 
(µM) 
M. luteus ATCC 9341 19 17 510 243 R 
B. subtilis ATCC 6633 19 R R 486 R 
S. aureus ATCC 29213 - 17 R 486 R 
S. epidermidis ATCC 
12228 
19 17 510 486 R 
P. aeruginosa ATCC 
27853 
78 68 R R R 
E. coli ATCC 25922 38 269 R R R 
K. pneumonae ATCC 
13883 
78 R R R R 
C. albicans ATCC 10231 19 68 R 243 R 
1From reference 42 
*The MIC determination is a qualitative assay and the estimated error is of the order of magnitude of the 
value. 
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Table 5. Hemolytic activity (HC50) and Cytotoxic Effect (IC50) of Double Chain Arginine 
Based-Surfactants. 
 Hemolysis 3T3 IC50 (μM) HaCaT IC50 (μM) HeLa IC50 (μM) 
Surfactant HC50 (μM)    NRU               MTT NRU               MTT       NRU               MTT 
LAM* 144 235 154 238 165   
LANHC10 761±39 34 ±9 27±7 119 ±49 21±12 40±36 16±4 
LANHC12 708±214 34±9.5 12±4 22±9 14±5 112±124 12±5 
LANHC14 412±62 30±10 20±8 28±9 23±10 62±21 38±23 
LANHC18 139±56 43±14 34±12 44±20 36±25 --- 36±8 
*From reference 42 
 Results expressed as mean ± standard error of at least 3 independent experiments 
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Figures 
Figure captions 
Figure  1. Chemical procedure for the synthesis of single and double chain arginine surfactants 
(LANHCx, x corresponds to the length of the second alkyl chain). 
 
Figure 2.  Conductivity versus concentration curves for the LANHC14 surfactants (■25ºC, ● 50ºC). 
Figure 3. Pure surfactant solutions at 25°C at three different concentrations (1, 2.5 and 5mM): a) 
LANHC10; b) LANHC12; c) LANHC14. 
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Figure 1 
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Figure 2 
Figure 2  
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